Nephrol Dial Transplant 2012; 27(1): 381-387

164. Baker, RJ, Senior, H, Clemenger, M, et al. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41(3): 670-675.

165. Lui, SL, Cheng, SW, Ng, F, et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function. Kidney Int 2005; 68(5): 2375-2380.

166. Tokgoz, B, Somdas, MA, Ucar, C, et al. Correlation between hearing loss and peritonitis frequency and administration of ototoxic intraperitoneal antibiotics in patients with CAPD. Ren Fail 2010; 32(2): 179-184

167. Wong, KM, Chan, YH, Cheung, CY, et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis 2001; 38(1): 127-131

168. Kitrunghaiboon, T, Puapatanakul, P, Chuengsaman, P, et al. Intraperitoneal cefepime monotherapy versus combination therapy of cefazolin plus ceftazidime for empirical treatment of CAPD-associated peritonitis: a multicenter, open-label, noninferiority, randomized, controlled trial. Am J Kidney Dis 2019; 74(5): 601-609

169. Li, PK, Ip, M, Law, MC, et al. Use of intraperitoneal cefepime as monotherapy in treatment of CAPD peritonitis. Perit Dial Int 2000; 20(2): 232-234.

170. Fontan, MP, Cambre, HD, Rodriguez-Carmona, A, et al. Treatment of peritoneal dialysis-related peritonitis with ciprofloxacin monotherapy: clinical outcomes and bacterial susceptibility over two decades. Perit Dial Int 2009; 29(3): 310-318.

171. Muthucumarana, K, Howson, P, Crawford, D, et al. The relationship between presentation and the time of initial administration of antibiotics with outcomes of peritonitis in peritoneal dialysis patients: the PROMPT study. Kidney Int Rep 2016; 1(2): 65-72

172. Oki, R, Tsuji, S, Hamasaki, Y, et al. Time until treatment initiation is associated with catheter survival in peritoneal dialysis-related peritonitis. Sci Rep 2021; 11(1): 6547

173. Dos Santos, A, Hernandes, RT, Montelli, AC, et al. Clinical and microbiological factors predicting outcomes of nonfermenting gram-negative bacilli peritonitis in peritoneal dialysis. Sci Rep 2021; 11(1): 12248

174. Lye, WC, Wong, PL, van der Straaten, JC, et al. A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Adv Perit Dial 1995; 11: 179-181.

Google Scholar | Medline

175. Varghese, JM, Roberts, JA, Wallis, SC, et al. Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study). Clin J Am Soc Nephrol 2012; 7(8): 1249-1256

176. Manley, HJ, Bailie, GR, Frye, R, et al. Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. J Am Soc Nephrol 2000; 11(7): 1310-1316

177. Roberts, DM, Ranganathan, D, Wallis, SC, et al. Pharmacokinetics of intraperitoneal cefafothin and cefazolin in patients being treated for peritoneal dialysis-associated peritonitis. Perit Dial Int 2016; 36(4): 415-420.

178. Peerapornratana, S, Chariyavilaskul, P, Kanjanabuch, T, et al. Short-Dwell cycling intraperitoneal cefazolin plus ceftazidime in peritoneal dialysis patients. Perit Dial Int 2017; 37(2): 218-224.

179. Tosukhowong, T, Eiam-Ong, S, Thamutok, K, et al. Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2001; 21(6): 587-594.

180. Agrawal, A, Agarwal, SK, Kaleekal, T, et al. Rifampicin and anti-hypertensive drugs in chronic kidney disease: pharmacokinetic interactions and their clinical impact. Indian J Nephrol 2016; 26(5): 322-328

181. Albin, HC, Demotes-Mainard, FM, Bouchet, JL, et al. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 1985; 38(3): 285-289

182. Leung, CB, Szeto, CC, Chow, KM, et al. Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis--a randomized controlled trial. Perit Dial Int 2004; 24(5): 440-446.

183. Albin, H, Ragnaud, JM, Demotes-Mainard, F, et al. Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis. Eur J Clin Pharmacol 1986; 31(4): 479-483

184. Bierhoff, M, Krutwagen, E, van Bommel, EF, et al. Listeria peritonitis in patients on peritoneal dialysis: two cases and a review of the literature. Neth J Med 2011; 69(10): 461-464.

Google Scholar | Medline

185. Boss, K, Wiegard-Szramek, I, Dziobaka, J, et al. Intraperitoneal ampicillin treatment for peritoneal dialysis-related peritonitis with listeria monocytogenes - a case report. BMC Nephrol 2020; 21(1): 404

186. Yip, T, Tse, KC, Ng, F, et al. Clinical course and outcomes of single-organism enterococcus peritonitis in peritoneal dialysis patients. Perit Dial Int 2011; 31(5): 522-528.

187. Lam, MF, Tang, BS, Tse, KC, et al. Ampicillin-sulbactam and amikacin used as second-line antibiotics for patients with culture-negative peritonitis. Perit Dial Int 2008; 28(5): 540-542.

188. Fitzpatrick, MA, Esterly, JS, Postelnick, MJ, et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam. Ann Pharmacother 2012; 46(7-8): e17.

189. Zaidenstein, R, Weissgarten, J, Dishi, V, et al. Pharmacokinetics of intraperitoneal piperacillin/tazobactam in patients on peritoneal dialysis with and without pseudomonas peritonitis. Perit Dial Int 2000; 20(2): 227-231.

190. Pasadakis, P, Thodis, E, Euthimiadou, A, et al. Treatment of CAPD peritonitis with clavulanate potentiated ticarcillin. Adv Perit Dial 1992; 8: 238-241.

Google Scholar | Medline

191. Fuiiano, G, Sepe, V, Viscione, M, et al. Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989; 9(4): 273-275.

192. Dratwa, M, Glupczynski, Y, Lameire, N, et al. Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis 1991; 13(Suppl 7): S645-S647

193. Gerig, JS, Bolton, ND, Swabb, EA, et al. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. Kidney Int 1984; 26(3): 308-318

194. Cheng, IK, Chan, CY, Wong, WT, et al. A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13(Suppl 2): S351-S354.

195. Chang, MJ, Namgung, H, Choi, HD, et al. Pharmacokinetics of clindamycin in the plasma and dialysate after intraperitoneal administration of clindamycin phosphoester to patients on continuous ambulatory peritoneal dialysis: an open-label, prospective, single-dose, two-institution study. Basic Clin Pharmacol Toxicol 2012; 110(6): 504-509

196. Saint Paul, LP, Ficheux, M, Debruyne, D, et al. Pharmacokinetics of 300 mg/d intraperitoneal daptomycin: new insight from the daptodP study. Perit Dial Int 2018; 38(6): 463-466.

197. Lin, SY, Ho, MW, Liu, JH, et al. Successful salvage of peritoneal catheter in unresolved methicillin-resistant Staphylococcus aureus peritonitis by combination treatment with daptomycin and rifampin. Blood Purif 2011; 32(4): 249-252

198. Huen, SC, Hall, I, Topal, J, et al. Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. Am J Kidney Dis 2009; 54(3): 538-541

199. Perez Melon, C, Borrajo Prol, M, Iglesias, E, et al. Daptomycin in peritoneal dialysis, intraperitoneal or intravenous. Nefrologia 2016; 36(4): 461-462

200. Gilmore, JF, Kim, M, LaSalvia, MT, et al. Treatment of enterococcal peritonitis with intraperitoneal daptomycin in a vancomycin-allergic patient and a review of the literature. Perit Dial Int 2013; 33(4): 353-357.

201. Kussmann, M, Baumann, A, Hauer, S, et al. Compatibility of fosfomycin with different commercial peritoneal dialysis solutions. Eur J Clin Microbiol Infect Dis 2017; 36(11): 2237-2242

202. Kussmann, M, Hauer, S, Pichler, P, et al. Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2018; 37(6): 1091-1098

203. Anwar, N, Merchant, M, Were, T, et al. A prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem versus vancomycin and netilmicin in the treatment of peritonitis on CAPD. Perit Dial Int 1995; 15(2): 167-171

204. Cheng, IK, Chan, CY, Wong, WT. A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1991; 11(1): 27-30.

205. Lynn, WA, Clutterbuck, E, Want, S, et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant enterococcus faecium with quinupristin/dalfopristin. Lancet 1994; 344(8928): 1025-1026

206. de Fijter, CW, Jakulj, L, Amiri, F, et al. Intraperitoneal meropenem for polymicrobial peritoneal dialysis-related peritonitis. Perit Dial Int 2016; 36(5): 572-573.

207. Ling, CW, Sud, K, Van, C, et al. Pharmacokinetics of culture-directed antibiotics for the treatment of peritonitis in automated peritoneal dialysis: a systematic narrative review. Perit Dial Int 2021; 41(3): 261-272.

208. Ma, Y, Geng, Y, Jin, L, et al. Serum vancomycin levels predict the short-term adverse outcomes of peritoneal dialysis-associated peritonitis. Perit Dial Int. Epub ahead of print 13 January 2022. DOI: 10.1177/08968608221064192.

Google Scholar

209. Vlaar, PJ, van Hulst, M, Benne, CA, et al. Intraperitoneal compared with intravenous meropenem for peritoneal dialysis-related peritonitis. Perit Dial Int 2013; 33(6): 708-709.

210. Liakopoulos, V, Leivaditis, K, Nikitidou, O, et al. Intermittent intraperitoneal dose of teicoplanin in peritoneal dialysis-related peritonitis. Perit Dial Int 2012; 32(3): 365-366.

211. Lupo, A, Rugiu, C, Bernich, P, et al. A prospective, randomized trial of two antibiotic regimens in the treatment of peritonitis in CAPD patients: teicoplanin plus tobramycin versus cephalothin plus tobramycin. J Antimicrob Chemother 1997; 40(5): 729-732

212. Falbo Dos Reis, P, Barretti, P, Marinho, L, et al. Pharmacokinetics of intraperitoneal vancomycin and amikacin in automated peritoneal dialysis patients with peritonitis. Front Pharmacol 2021; 12: 658014

213. Lam, E, Ting Kayla Lien, Y, Kraft, WK, et al. Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis. Clin Transl Sci. Epub ahead of print 9 November 2021. DOI: 10.1111/cts.13182.

Google Scholar

214. De Vriese, AS, Vandecasteele, SJ. Vancomycin: the tale of the vanquisher and the pyrrhic victory. Perit Dial Int 2014; 34(2): 154-161.

Google Scholar | Medline

215. Matuszkiewicz-Rowinska, J. Update on fungal peritonitis and its treatment. Perit Dial Int 2009; 29(Suppl 2): S161-S165.

216. Dahl, NV, Foote, EF, Searson, KM, et al. Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis. Ann Pharmacother 1998; 32(12): 1284-1289.

217. Roberts, DM, Kauter, G, Ray, JE, et al. Intraperitoneal voriconazole in a patient with Aspergillus peritoneal dialysis peritonitis. Perit Dial Int 2013; 33(1):
92-93.

218. Kussmann, M, Schuster, L, Zeitlinger, M, et al. The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against enterococcus faecalis. Eur J Clin Microbiol Infect Dis 2015; 34(11): 2257-2263

219. Szeto, CC, Ng, JK, Chow, KM, et al. Treatment of enterococcal peritonitis in peritoneal dialysis patients by oral amoxicillin or intra-peritoneal vancomycin: a retrospective study. Kidney Blood Press Res 2017; 42(5): 837-843

220. Shalit, I, Greenwood, RB, Marks, MI, et al. Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1986; 30(1): 152-156

221. Lee, C, Walker, SAN, Palmay, L, et al. Steady-State pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis patients: brief report. Perit Dial Int 2018; 38(1): 73-76.

222. Verbanck, JJ, Verlinde, AM, Verbanck, MI, et al. Campylobacter jejuni II peritonitis in a CCPD patient: cure by oral clarithromycin. Perit Dial Int 1999; 19(1): 85-86.

223. Ma, TK, Lee, KP, Chow, KM, et al. Campylobacter peritonitis complicating peritoneal dialysis: a review of 12 consecutive cases. Perit Dial Int 2013; 33(2): 189-194.

224. O'Riordan, J, Bhally, HS, Salmon, AH, et al. Successful treatment of carbapenemase producing enterobacteriaceae peritonitis: 'old therapy for a new bug'. Perit Dial Int 2020; 40(1): 100-102.

225. Cheung, CY, Chan, SY, Yeung, CS, et al. Carbapenem resistant enterobacteriaceae as a cause of peritonitis in a peritoneal dialysis patient. Nephrology (Carlton) 2016; 21(10): 906-907

226. Koomanachai, P, Landersdorfer, CB, Chen, G, et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 2014; 58(1): 440-446

227. Van Matre, ET, Teitelbaum, I, Kiser, TH. Intravenous and intraperitoneal pharmacokinetics of dalbavancin in peritoneal dialysis patients. Antimicrob Agents Chemother 2020; 64(5): e02089-19.

228. Cardone, KE, Lodise, TP, Patel, N, et al. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6(5): 1081-1088

229. Cardone, KE, Grabe, DW, Kulawy, RW, et al. Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 2012; 56(2): 725-730

230. Cheng, IK, Fang, GX, Chau, PY, et al. A randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD. Perit Dial Int 1998; 18(4): 371-375.

231. Unal, A, Agkus, C, Kocigit, I, et al. Peritoneal dialysis-related peritonitis caused by vancomycin-resistant Enterococcus faecium. Ther Apher Dial 2011; 15(1): 115-116

232. Song, J, Seo, JW, Kwon, YE, et al. Successful treatment of vancomycin-resistant enterococcus peritonitis using linezolid without catheter removal in a peritoneal dialysis patient. Perit Dial Int 2014; 34(2): 235-239

233. Kawasui, H, Tsuji, Y, Ogami, C, et al. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol Toxicol 2021; 22(1): 13

234. Xu, R, Yang, Z, Qu, Z, et al. Intraperitoneal vancomycin plus either oral moxifloxacin or intraperitoneal ceftazidime for the treatment of peritoneal dialysis-related peritonitis: a randomized controlled pilot study. Am J Kidney Dis 2017; 70(1): 30-37

235. Skalioti, C, Tsaganos, T, Stamatiadis, D, et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 2009; 29(5): 575-579.

236. Moso, MA, Macesic, N. Peritoneal dialysis-related peritonitis with carbapenem-resistant Klebsiella pneumoniae and vancomycin-resistant Enterococcus faecium. Open Forum Infect Dis 2021; 8(1): ofaa525

237. Scheetz, MH, Reddy, P, Nicolau, DP, et al. Peritoneal fluid penetration of tigecycline. Ann Pharmacother 2006; 40(11): 2064-2067.

238. Celic, A, Cirit, M, Tunger, A, et al. Treatment of CAPD peritonitis with oral trimethoprim/sulfamethoxazole and intraperitoneal aminoglycoside combination. Perit Dial Int 1999; 19(3): 284-285.

239. Mahoney, MV. Clarification of trimethoprim/sulfamethoxazole dose in CAPD. Perit Dial Int 2015; 35(1): 116-118.

240. Wong, PN, Lo, KY, Tong, GM, et al. Treatment of fungal peritonitis with a combination of intravenous amphotericin B and oral flucytosine, and delayed catheter replacement in continuous ambulatory peritoneal dialysis. Perit Dial Int 2008; 28(2): 155-162.

241. Serna, JH, Wanger, A, Dosekun, AK. Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis. Am J Kidney Dis 2003; 42(3): E14-E17

242. Franconiери, F, Bonhomme, J, Doriot, A, et al. Fungal peritonitis caused by Rhodotorula mucilaginosa in a CAPD patient treated with liposomal amphotericin B: a case report and literature review. Perit Dial Int 2018; 38(1): 69-73.

243. Gioia, F, Gomez-Lopez, A, Alvarez, ME, et al. Pharmacokinetics of echinocandins in suspected candida peritonitis: a potential risk for resistance. Int J Infect Dis 2020; 101: 24-28

244. Tobudic, S, Donath, O, Vychtila, A, et al. Stability of anidulafungin in two standard peritoneal dialysis fluids. Perit Dial Int 2014; 34(7): 798-802.

245. Emami, S, Lew, SQ. Candida glabrata PD-associated peritonitis: a case report. Perit Dial Int 2018; 38(5): 391-392.

246. Beredaki, MI, Arendrup, MC, Andes, D, et al. The role of new posaconazole formulations in the treatment of Candida albicans infections: data from an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother 2021; 65(4): e01922-20

247. Whitty, R, Bargman, JM, Kiss, A, et al. Residual kidney function and peritoneal dialysis-associated peritonitis treatment outcomes. Clin J Am Soc Nephrol 2017; 12(12): 2016-2022

248. Lam, E, Lien, YTK, Kraft, WK, et al. Vancomycin in peritoneal dialysis: clinical pharmacology considerations in therapy. Perit Dial Int 2020; 40(4): 384-393.

249. Chang, WM, Cheng, E, Shalansky, K, et al. Evaluation of intraperitoneal vancomycin in peritoneal dialysis-associated peritonitis. Perit Dial Int. Epub ahead of print 21 October 2021. DOI: 10.1177/08968608211051579.

250. Stevenson, S, Tang, W, Cho, Y, et al. The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis. Perit Dial Int 2015; 35(2): 222-228

251. Mulhern, JG, Braden, GL, O'Shea, MH, et al. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis 1995; 25(4): 611-615

252. Dahlan, R, Lavoie, S, Biyani, M, et al. A high serum vancomycin level is associated with lower relapse rates in coagulase-negative staphylococcal peritonitis. Perit Dial Int 2014; 34(2): 232-235

253. Lortholdy, O, Tod, M, Cohen, Y, et al. Aminoglycosides. Med Clin North Am 1995; 79(4): 761-787

254. Rubin, J. Tobramycin absorption from the peritoneal cavity. Perit Dial Int 1990; 10(4): 295-297.

255. Tang, W, Cho, Y, Hawley, CM, et al. The role of monitoring gentamicin levels in patients with gram-negative peritoneal dialysis-associated peritonitis. Perit Dial Int 2014; 34(2): 219-226.

256. van der Hulst, RJ, Boeschen, EW, Nielsen, FW, et al. Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. ORL J Otorhinolaryngol Relat Spec 1991; 53(1): 19-22

257. Johnson, DW. Do antibiotic levels need to be followed in treating peritoneal dialysis-associated peritonitis? Semin Dial 2011; 24(4): 445-446

258. Sinswat, P, Wu, WJ, Sha, SH, et al. Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. Kidney Int 2000; 58(6): 2525-2532

259. Warady, BA, Reed, L, Murphy, G, et al. Aminoglycoside ototoxicity in pediatric patients receiving long-term peritoneal dialysis. Pediatr Nephrol 1993; 7(2): 178-181

260. Chong, TK, Piraino, B, Bernardini, J. Vestibular toxicity due to gentamicin in peritoneal dialysis patients. Perit Dial Int 1991; 11(2): 152-155.

261. Tokgoz, B, Ucar, C, Kocigit, I, et al. Protective effect of N-acetylcysteine from drug-induced ototoxicity in ureaemic patients with CAPD peritonitis. Nephrol Dial Transplant 2011; 26(12): 4073-4078

262. Naranjo, A, Kocigit, I, San, F, et al. Long-term protective effect of N-acetylcysteine against amikacin-induced ototoxicity in end-stage renal disease: a randomized trial. Perit Dial Int 2018; 38(1): 57-62.

263. Kocigit, I, Vural, A, Unal, A, et al. Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis. Eur Arch Otorhinolaryngol 2015; 272(10): 2611-2620

264. Feldman, L, Efrati, S, Eviatar, A, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 2007; 72(3):359-363

265. Kranzer, K, Elamin, WF, Cox, H, et al. A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. Thorax 2015; 70(11): 1070-1077

266. Kussmann, M, Ferth, A, Obermuller, M, et al. Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. Sci Rep 2019; 9(1): 6512

267. Fernandez-Varon, E, Marin, P, Espuny, A, et al. Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianae PD1 1.36% and Dianae PD1 3.86%). J Clin Pharm Ther 2006; 31(6): 641-643

268. Kussmann, M, Schuster, L, Wrenger, S, et al. Influence of different peritoneal dialysis fluids on the in vitro activity of cefepime, ciprofloxacin, ertapenem, meropenem and tobramycin against Escherichia coli. Perit Dial Int 2016; 36(6): 662-668.

269. How, PP, Fischer, JH, Arruda, JA, et al. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin J Am Soc Nephrol 2007; 2(6): 1235-1240

270. Kays, MB, Overholser, BR, Mueller, BA, et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 2003; 42(6): 1253-1259

271. Golper, TA, Hartstein, AI, Morthland, VH, et al. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1987; 31(11): 1787-1790

272. So, SW, Chen, L, Woo, AY, et al. Stability and compatibility of antibiotics in peritoneal dialysis solutions. Clin Kidney J 2022. DOI: 10.1093/ckj/sfac012.

273. Stab, R, Naecker, S, Wallis, SC, et al. Stability of Antibiotics for Intraperitoneal administration in extraneal 7.5% iodexin peritoneal dialysis bags (STAB Study). Perit Dial Int 2016; 36(4): 421-426

274. Dooley, DP, Tyler, JR, Wortham, WG, et al. Prolonged stability of antimicrobial activity in peritoneal dialysis solutions. Perit Dial Int 2003; 23(1): 58-62.

275. de Vin, F, Rutherford, P, Faict, D. Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 2009; 29(1): 5-15.

276. Williamson, JC, Volles, DF, Lynch, PL, et al. Stability of cefepime in peritoneal dialysis solution. Ann Pharmacother 1999; 33(9): 906-909.

277. Deslandes, G, Gregoire, M, Bouquie, R, et al. Stability and compatibility of antibiotics in peritoneal dialysis solutions applied to automated peritoneal dialysis in the pediatric population. Perit Dial Int 2016; 36(6): 676-679.

278. Mendes, K, Harmanjeet, H, Sedeeq, M, et al. Stability of meropenem and piperacillin/Tazobactam with heparin in various peritoneal dialysis solutions. Perit Dial Int 2018; 38(6): 430-440.
279. Harmanjeet, H, Jani, H, Zaidi, STR, et al. Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Perit Dial Int 2020; 40(5): 470-476.

280. Fish, R, Nipah, R, Jones, C, et al. Intraperitoneal vancomycin concentrations during peritoneal dialysis-associated peritonitis: correlation with serum levels. Perit Dial Int 2012; 32(3): 332-338.

281. Triyawatanyu, P, Chariyavilaskul, P, Phaisal, W, et al. Intraperitoneal cefazolin and ceftazidime during short-dwell exchange in peritoneal dialysis patients with peritonitis. Perit Dial Int 2020; 40(2): 179-184.

282. Ejlersen, E, Brandi, L, Lokkegaard, H, et al. Is initial (24 hours) lavage necessary in treatment of CAPD peritonitis? Perit Dial Int 1991; 11(1): 38-42.

283. Wong, SS, Lau, WY, Tse, YY, et al. Randomized controlled trial on adjunctive lavage for severe peritonitis. Perit Dial Int; 2019; 39(5): 447-454.

284. Demoulin, N, Goffin, E. Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative staphylococcus peritonitis. Perit Dial Int 2009; 29(5): 548-553.

285. Tong, MK, Leung, KT, Siu, YP, et al. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis. J Nephrol 2005; 18(2): 204-208.

286. Gadallah, MF, Tamayo, A, Sandborn, M, et al. Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients. Adv Perit Dial 2000; 16: 233-236.

287. Innes, A, Burden, RP, Finch, RG, et al. Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: a double-blind clinical trial. Nephrol Dial Transplant 1994; 9(7): 797-799.

288. Williams, AJ, Boletis, I, Johnson, BF, et al. Tenckhoff catheter replacement or intraperitoneal urokinase: a randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis. Perit Dial Int 1989; 9(1): 65-67.

289. Vlaanderen, K, Bos, HJ, de Fijter, CW, et al. Short dwell times reduce the local defence mechanism of chronic peritoneal dialysis patients. Nephron 1991; 57(1): 29-35.

290. Chow, KM, Szeto, CC, Kwan, BC, et al. Randomized controlled study of icodextrin on the treatment of peritoneal dialysis patients during acute peritonitis. Nephrol Dial Transplant 2014; 29(7): 1438-1443.

291. Chow, KM, Szeto, CC, Cheung, KK, et al. Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis. Clin J Am Soc Nephrol 2006; 1(4): 768-773.

292. Nochaiwong, S, Ruengorn, C, Koyratkoson, K, et al. A clinical risk prediction tool for peritonitis-associated treatment failure in peritoneal dialysis patients. Sci Rep 2018; 8(1): 14797.

293. Choi, P, Nemati, E, Banerjee, A, et al. Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. Am J Kidney Dis 2004; 43(1): 103-111.

294. Lu, W, Kwan, BC, Chow, KM, et al. Peritoneal dialysis-related peritonitis caused by Pseudomonas species: insight from a post-millennial case series. PLoS One 2018; 13(5): e0196499.

295. Xu, R, Chen, Y, Luo, S, et al. Clinical characteristics and outcomes of peritoneal dialysis-related peritonitis with different trends of change in effluent white cell count: a longitudinal study. Perit Dial Int 2013; 33(4): 436-444.

296. Tantiyavarong, P, Traitanon, O, Chuengsaman, P, et al. Dialysate white blood cell change after initial antibiotic treatment represented the patterns of response in peritoneal dialysis-related peritonitis. Int J Nephrol 2016; 2016: 6217135.

297. Szeto, CC, Kwan, BC, Chow, KM, et al. Recurrent and relapsing peritonitis: causative organisms and response to treatment. Am J Kidney Dis 2009; 54(4): 702-710.

298. Burke, M, Hawley, CM, Badve, SV, et al. Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study. Am J Kidney Dis 2011; 58(3): 429-436.

299. Szeto, CC, Kwan, BC, Chow, KM, et al. Repeat peritonitis in peritoneal dialysis: retrospective review of 181 consecutive cases. Clin J Am Soc Nephrol 2011; 6(4): 827-833.

300. Thirugnanasambathan, T, Hawley, CM, Badve, SV, et al. Repeated peritoneal dialysis-associated peritonitis: a multicenter registry study. Am J Kidney Dis 2012; 59(1): 84-91.

301. Reis, M, Ribeiro, C, Gomes, AM, et al. Repeat and relapsing peritonitis microbiological trends and outcomes: a 21-year single-center experience. Int J Nephrol 2021; 2021: 6662488.

302. Swartz, R, Messana, J, Reynolds, J, et al. Simultaneous catheter replacement and removal in refractory peritoneal dialysis infections. Kidney Int 1991; 40(6): 1160-1165.

303. Crabtree, JH, Siddiqi, R.A. Simultaneous catheter replacement for infectious and mechanical complications without interruption of peritoneal dialysis. Perit Dial Int 2016; 36(2): 182-187.

304. Viron, C, Lobbedez, T, Lanot, A, et al. Simultaneous removal and reinsertion of the PD catheter in relapsing peritonitis. Perit Dial Int 2019; 39(3): 282-288.

305. Szeto, CC, Ng, JK, Wing-Shing Fung, W, et al. Extended antibiotic therapy for the prevention of relapsing and recurrent peritonitis in peritoneal dialysis patients: a randomized controlled trial. Clin Kidney J 2021; 14(3): 991-997.

306. Szeto, CC, Lai, KB, Kwan, BC, et al. Bacteria-derived DNA fragment in peritoneal dialysis effluent as a predictor of relapsing peritonitis. Clin J Am Soc Nephrol 2013; 8(11): 1935-1941.

307. Camargo, CH, Cunha Mde, L, Caramori, JC, et al. Peritoneal dialysis-related peritonitis due to coagulase-negative staphylococcus: a review of 115 cases in a Brazilian center. Clin J Am Soc Nephrol 2014; 9(6): 1074-1081.

308. Prasad, JM, Negron, O, Du, X, et al. Host fibrinogen drives antimicrobial function in Staphylococcus aureus peritonitis through bacterial-mediated prothrombin activation. Proc Natl Acad Sci U S A 2021; 118(1): e2009837118.

309. Chen, HC, Shieh, CC, Sung, JM. Increasing staphylococcus species resistance in peritoneal dialysis-related peritonitis over a 10-year period in a single Taiwanese Center. Perit Dial Int 2018; 38(4): 266-270.

310. Kitterer, D, Latus, J, Pohlmann, C, et al. Microbiological surveillance of peritoneal dialysis associated peritonitis: antimicrobial susceptibility profiles of a referral center in GERMANY over 32 years. PLoS One 2015; 10(9): e0135969.

311. Wang, HH, Huang, CH, Kuo, MC, et al. Microbiology of peritoneal dialysis-related infection and factors of refractory peritoneal dialysis related peritonitis: a ten-year single-center study in Taiwan. J Microbiol Immunol Infect 2019; 52(5): 752-759.

312. Szeto, CC, Kwan, BC, Chow, KM, et al. Coagulase negative staphylococcal peritonitis in peritoneal dialysis patients: review of 232 consecutive cases. Clin J Am Soc Nephrol 2008; 3(1): 91-97

313. Heywood, A, Bargman, JM. Coagulase-negative staphylococcal peritonitis: Outcomes of cephalosporin-resistant strains. Adv Perit Dial 2010; 26: 34-36.

314. Fahim, M, Hawley, CM, McDonald, SP, et al. Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases. Nephrol Dial Transplant 2010; 25(10): 3386-3392

315. Mitra, A, Teitelbaum, I. Is it safe to simultaneously remove and replace infected peritoneal dialysis catheters? Review of the literature and suggested guidelines. Adv Perit Dial 2003; 19: 255-259.

316. Haivas, CD, Teitelbaum, I. Eradication of repeated episodes of coagulase-negative Staphylococcus peritonitis: a multipronged approach. Perit Dial Int 2019; 39(6): 568-570.

317. Szeto, CC, Chow, KM, Kwan, BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases. Clin J Am Soc Nephrol 2007; 2(2): 245-251

318. Govindarajulu, S, Hawley, CM, McDonald, SP, et al. Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases. Perit Dial Int 2010; 30(3): 311-319.

319. Tobudic, S, Kern, S, Kussmann, M, et al. Effect of peritoneal dialysis fluids on activity of teicoplanin against methicillin-resistant Staphylococcus aureus biofilm. Perit Dial Int 2019; 39(3): 293-294.

320. O'Shea, S, Hawley, CM, McDonald, SP, et al. Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. BMC Nephrol 2009; 10: 19

321. Santos, JE, Rodriguez Magarinos, C, Garcia Gago, L, et al. Long-term trends in the incidence of peritoneal dialysis-related peritonitis disclose an increasing relevance of streptococcal infections: a longitudinal study. PLoS One 2020; 15(12): e0244283.

322. Liu, Y, Cheng, BC, Liu, JW, et al. Viridans Streptococcus peritonitis in peritoneal dialysis: clinical characteristics and comparison with concurrent polymicrobial infection. BMC Nephrol 2018; 19(1): 271

323. Chao, CT, Lee, SY, Yang, WS, et al. Viridans streptococci in peritoneal dialysis peritonitis: clinical courses and long-term outcomes. Perit Dial Int 2015; 35(3): 333-341.

324. Htay, H, Cho, Y, Pascoe, EM, et al. Outcomes of Corynebacterium peritonitis: a multicenter registry analysis. Perit Dial Int 2017; 37(6): 619-626.

325. Barraclough, K, Hawley, CM, McDonald, SP, et al. Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases. Nephrol Dial Transplant 2009; 24(12): 3834-3839

326. Szeto, CC, Chow, KM, Chung, KY, et al. The clinical course of peritoneal dialysis-related peritonitis caused by Corynebacterium species. Nephrol Dial Transplant 2005; 20(12): 2793-2796

327. Chao, CT, Huang, JW, Yen, CJ. A rare and under-recognized pathogen in peritoneal dialysis peritonitis: Corynebacterium jeikeium. Perit Dial Int 2013; 33(5): 580-581.

328. Schiff, H, Mucke, C, Lang, SM. Exit-site infections by non-diphtheria corynebacteria in CAPD. Perit Dial Int 2004; 24(5): 454-459.

329. McMullen, AR, Anderson, N, Wallace, MA, et al. When good bugs go bad: epidemiology and antimicrobial resistance profiles of Corynebacterium striatum, an emerging multidrug-resistant, opportunistic pathogen. Antimicrob Agents Chemother 2017; 61(11): e01111-17

330. Edey, M, Hawley, CM, McDonald, SP, et al. Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. Nephrol Dial Transplant 2010; 25(4): 1272-1278

331. Nzana, VB, Rohit, A, George, D, et al. Twenty-one episodes of peritonitis in a continuous ambulatory peritoneal dialysis patient: what is the root cause? Indian J Med Microbiol 2018; 36(2): 282-284

332. Piraino, B. Peritoneal dialysis catheter replacement: "Save the patient and not the catheter". Semin Dial 2003; 16(1): 72-75

333. Yeung, CS, Cheung, CY, Chan, YH, et al. Risk factors and outcomes of vancomycin-resistant enterococcus colonization in patients on peritoneal dialysis: a single-center study in Hong Kong. Perit Dial Int 2017; 37(5): 556-561.

334. Zacharioudakis, IM, Zervou, FN, Ziakas, PD, et al. Vancomycin-resistant enterococcal colonization among dialysis patients: a meta-analysis of prevalence, risk factors, and significance. Am J Kidney Dis 2015; 65(1): 88-97

335. Bailey, EM, Faber, MD, Nafziger, DA. Linezolid for treatment of vancomycin-resistant enterococcal peritonitis. Am J Kidney Dis. 2001;38(4): E20

336. Hassoun, AA, Coomer, RW, Mendez-Vigo, L. Intraperitoneal daptomycin used to successfully treat vancomycin-resistant enterococcus peritonitis. Perit Dial Int 2009; 29(6): 671-673.

337. Troidle, L, Kliger, AS, Gorban-Brennan, N, et al. Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. Kidney Int 1996; 50(4): 1368-1372
338. Johnson, CA, Taylor, CA, Zimmerman, SW, et al. Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients. Antimicrob Agents Chemother 1999; 43(1): 152–156

339. Siva, B, Hawley, CM, McDonald, SP, et al. Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases. Clin J Am Soc Nephrol 2009; 4(5): 957–964

340. Szeto, CC, Chow, KM, Leung, CB, et al. Clinical course of peritonitis due to pseudomonas species complicating peritoneal dialysis: a review of 104 cases. Kidney Int 2001; 59(6): 2309–2315

341. Htay, H, Cho, Y, Pascoe, EM, et al. Outcomes of acinetobacter peritonitis in peritoneal dialysis patients: a multicenter registry analysis. Perit Dial Int 2018; 38(4): 257–265

342. Li, PH, Cheng, VC, Yip, T, et al. Epidemiology and clinical characteristics of acinetobacter peritoneal dialysis-related peritonitis in Hong Kong with a perspective on multi-drug and carbapenem resistance. Perit Dial Int 2017; 37(2): 177–182.

343. Taylor, G, McKenzie, M, Buchanan-Chell, M, et al. Peritonitis due to Stenotrophomonas maltophilia in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2019; 39(3): 259–262.

344. Tzanetou, K, Triantaphillis, G, Tsoutsos, D., et al. Stenotrophomonas maltophilia peritonitis in CAPD patients: susceptibility to antibiotics and treatment outcome: a report of five cases. Perit Dial Int 2004; 24(4): 401–404.

345. Szeto, CC, Li, PK, Leung, CB, et al. Xanthomonas maltophilia peritonitis in uremic patients receiving continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1997; 29(1): 91–95

346. Abbott, IJ, Peleg, AY. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med 2015; 36(1): 99–110

347. Brown, GR. Cotrimoxazole - optimal dosing in the critically ill. Ann Intensive Care 2014; 4: 13

348. Junco, SJ, Bowman, MC, Turner, RB. Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy. Int J Antimicrob Agents 2021; 58(2): 10636.

349. Ko, JH, Kang, CJ, Comejo-Juarez, P, et al. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis. Clin Microbiol Infect 2019; 25(5): 546–554

350. Wu, H, Yi, C, Zhang, D, et al. Changes of antibiotic resistance over time among Escherichia coli peritonitis in Southern China. Perit Dial Int. Epub ahead of print 28 September 2021; DOI: 10.1177/08968608211045272.

351. Jarvis, EM, Hawley, CM, McDonald, SP, et al. Predictors, treatment, and outcomes of non-pseudomonas gram-negative peritonitis. Kidney Int 2010; 78(4): 408–414

352. Hsueh, PR, Badal, RE, Hawser, SP, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for monitoring antimicrobial resistance trends). Int J Antimicrob Agents 2010; 36(5): 408–414

353. Dias, RCB, Vieira, MA, Moro, AC, et al. Characterization of Escherichia coli obtained from patients undergoing peritoneal dialysis and diagnosed with peritonitis in a Brazilian centre. J Med Microbiol 2019; 68(9): 1330–1340

354. Lin, WH, Tseng, CC, Wu, AB, et al. Clinical and microbiological characteristics of peritoneal dialysis-related peritonitis caused by Escherichia coli in southern Taiwan. Eur J Clin Microbiol Infect Dis 2018; 37(9): 1699–1707

355. Wang, TZ, Kodiyanplakkal, RPL, Calfee, DP. Antimicrobial resistance in nephrology. Nat Rev Nephrol 2019; 15(8): 463–481

356. Iredell, J, Brown, J, Tagk, K. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. BMJ 2016; 352: h6420

357. Hughes, S, Gilchrist, M, Heard, K, et al. Treating infections caused by carbapenemase-producing enterobacterales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA pharmacy infection network (PIN). JAC Antimicrob Resist 2020; 2(3): dla0075

358. Ma, TK, Chow, KM, Kwan, BC, et al. Peritoneal-dialysis related peritonitis caused by Gordonia species: report of four cases and literature review. Nephrology (Carlton) 2014; 19(7): 379–383

359. Lam, JY, Wu, AK, Leung, WS, et al. Gordonia species as emerging causes of continuous-ambulatory-peritoneal-dialysis-related peritonitis identified by 16S rRNA and secA1 gene sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). J Clin Microbiol 2015; 53(2): 671–676

360. Poliquin, PG, Lagace-Wiens, P, Verrelli, M, et al. Pasteurella species peritoneal dialysis-associated peritonitis: household pets as a risk factor. Can J Infect Dis Med Microbiol. 2015; 26(1): 52–55

361. Harwell, CM, Newman, LN, Cacho, CP, et al. Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis. Perit Dial Int 1997; 17(6): 586–594.

362. Trinh, CC, Bargman, JM. Utility of abdominal imaging in peritoneal dialysis patients presenting with peritonitis. Can J Kidney Health Dis 2020; 7: 2054358120964115.

363. Szeto, CC, Chow, KM, Wong, TY, et al. Conservative management of polymicrobial peritonitis complicating peritoneal dialysis--a series of 140 consecutive cases. Am J Med 2002; 113(9): 728–733.

364. Ribera-Sanchez, R, Perez-Fontan, M, Lopez-Iglesias, A, et al. Comprehensive approach to peritoneal dialysis-related peritonitis by enteric microorganisms. comparison between single organism and polymicrobial infections. Perit Dial Int 2018; 38(2): 139–146.

365. Nadeau-Fredette, AC, Bargman, JM. Characteristics and outcomes of fungal peritonitis in a modern North American cohort. Perit Dial Int 2015; 35(1): 78–84.

366. Chang, TI, Kim, HW, Park, JT, et al. Early catheter removal improves patient survival in peritoneal dialysis patients with fungal peritonitis: results of ninety-four episodes of fungal peritonitis at a single center. Perit Dial Int 2011; 31(1): 60–66.

367. Giacobino, J, Montelli, AC, Barrett, P, et al. Fungal peritonitis in patients undergoing peritoneal dialysis (PD) in Brazil: molecular identification, biofilm production and antifungal susceptibility of the agents. Med Mycol 2016; 54(7): 725–732

368. Tobudic, S, Harrison, N, Forstner, C, et al. Effect of peritoneal dialysis fluids on activity of echinocandins against Candida spp. biofilm. Med Mycol 2017; 55(7): 7999–7993

369. Peng, LW, Lien, YH. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. Am J Kidney Dis 2005; 45(1): 162–166

370. Dotis, J, Kondou, A, Koukloumperi, E, et al. Aspergillus peritonitis in peritoneal dialysis patients: a systematic review. J Mycol Med 2020; 30(4): 101037

371. Miles, R, Hawley, CM, McDonald, SP, et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int 2009; 76(6): 622–628

372. Bunke, M, Brier, ME, Golper, TA. Culture-negative CAPD peritonitis: the network 9 Study. Adv Perit Dial 1994; 10: 174–178.

373. Htay, H, Cho, Y, Pascoe, EM, et al. Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. Perit Dial Int 2020; 40(1): 47–56.

374. Chen, KH, Chang, CT, Weng, SM, et al. Culture-negative peritonitis: a fifteen-year review. Ren Fail 2007; 29(2): 177–181

375. Akpolat, T. Tuberculous peritonitis. Perit Dial Int 2009; 29(Suppl 2): S166–S169.

376. Talwani, R, Horvath, JA. Tuberculous peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: case report and review. Clin Infect Dis 2000; 31(1): 70–75

377. Thomson Benjamin, KA, Stephen, V, Bogdan, M. Mycobacterium tuberculosis peritonitis in peritoneal dialysis patients: a scoping review. Nephrology (Carlton) 2021; 27(2): 133–144

378. Al Sahlawi, M, Bargman, JM, Perl, J. Peritoneal dialysis-associated peritonitis: suggestions for management and mistakes to avoid. Kidney Med 2020; 2(4): 467–475

379. Lye, WC. Rapid diagnosis of Mycobacterium tuberculosis peritonitis in two continuous ambulatory peritoneal dialysis patients, using DNA amplification by polymerase chain reaction. Adv Perit Dial 2002; 18: 154–157.

380. Ahn, C, Oh, KH, Kim, K, et al. Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin. Perit Dial Int 2003; 23(4): 362–367.

381. Si, M, Li, H, Chen, Y, et al. Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. BMJ Case Rep 2018; 2018; bcr2017223187.

382. Unsal, A, Ahbap, E, Basturk, T, et al. Tuberculosis in dialysis patients: a nine-year retrospective analysis. J Infect Dev Ctries 2013; 7(3): 208–213

383. Washida, N, Itoh, H. The role of non-tuberculous mycobacteria in peritoneal dialysis-related infections: a literature review. Contrib Nephrol 2018; 196: 155–161

384. Fung, WW, Chow, KM, Li, PK, et al. Clinical course of peritoneal dialysis-related peritonitis due to non-tuberculosis mycobacterium - A single centre experience spanning 20 years. Perit Dial Int. Epub ahead of print 3 September 2021. DOI: 10.1177/08968608211042434.

385. Jiang, SH, Roberts, DM, Clayton, PA, et al. Non-tuberculous mycobacterial PD peritonitis in Australia. Int Urol Nephrol 2013; 45(5): 1423–1428

386. Bnaya, A, Wiener-Well, Y, Soetendorp, H, et al. Nontuberculous mycobacteria infections of peritoneal dialysis patients: a multicenter study. Perit Dial Int 2021; 41(3): 284–291.

387. Renaud, CJ, Subramanian, S, Tambyah, PA, et al. The clinical course of rapidly growing nontuberculous mycobacterial peritoneal dialysis infections in Asians: a case series and literature review. Nephrology (Carlton) 2011; 16(2): 174–179

388. Imam, O, Al-Zubaidi, K, Janahi, M, et al. Peritoneal dialysis-associated peritonitis caused by Mycobacterium abscessus in children-a case report. Open Forum Infect Dis 2021; 8(1): ofaa579

389. Kojya, S, Shiohira, H, Sunagawa, Y, et al. Therapeutic drug monitoring in peritoneal dialysis: a case of nontuberculous mycobacterium catheter-related infection treated with amikacin. Clin Case Rep. 2020; 8(6): 995–998

390. Song, Y, Wu, J, Yan, H, et al. Peritoneal dialysis-associated nontuberculous mycobacterium peritonitis: a systematic review of reported cases. Nephrol Dial Transplant 2012; 27(4): 1639–1644

391. Bonomini, M, Borras, FE, Troya-Saborido, M, et al. Proteomic research in peritoneal dialysis. Int J Mol Sci 2020; 21(15): 5489.

392. Takeuchi, T, Ohno, H, Satoh-Takayama, N. Understanding the immune signature fingerprint of peritoneal dialysis-related peritonitis. Kidney Int 2017; 92(1): 16–18.

393. Verma, A, Chitalia, VC, Waikar, SS, et al. Machine learning applications in nephrology: a bibliometric analysis comparing kidney studies to other medicine subspecialties. Kidney Med 2021; 3(5): 762–767

394. Fung, WW, Li, PK. Recent advances on novel diagnostic testing for peritoneal dialysis related peritonitis. Kidney Res Clin Pract. Epub ahead of print 21 January 2022. DOI:10.23876/j.krcp.21.204.

395. Bennett, PN, Bohm, C, Harasemiw, O, et al. Physical activity and exercise in peritoneal dialysis: international society for peritoneal dialysis and the global renal exercise network practice recommendations. Perit Dial Int 2022; 42(1): 8–24.